On the same day as Roche's Pharma Day in London, the biopharma giant revealed a high-dollar deal with Chinese-American ...

IMTOZ trial findings and subsequent approval of Isa-VRd regimen for transplant-ineligible myeloma suggested the combo as a ...

Apellis Pharmaceuticals' Syfovre, despite initial safety concerns, shows strong revenue growth and is nearing profitability.

Japan Pruritus Therapeutics Market was valued at US$ 582.2 million in 2023 and is estimated to surpass the market size of US$ 1,011.5 million by 2032 at a CAGR of 6.33% during the forecast period 2024 ...